Aileron Therapeutics (Aileron Therapeutics) Short Percentage of Float

View and export this data going back to 2017. Start your Free Trial

What is Aileron Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Aileron Therapeutics's Short Percentage of Float

For the Biotechnology subindustry, Aileron Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aileron Therapeutics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aileron Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Aileron Therapeutics's Short Percentage of Float falls into.

Aileron Therapeutics (Aileron Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aileron Therapeutics Inc (NAS:ALRN) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

N/A

Address

285 Summer Street, Unit 101, Boston, MA, USA, 02210

Website

https://www.aileronrx.com

Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects.

Executives

James Brian Windsor	officer: See Remarks	2600 VIA FORTUNA, SUITE 360, AUSTIN TX 78746
William Fairey	director	C/O CHEMOCENTRYX, INC., 850 MAUDE AVE., MOUNTAIN VIEW CA 94043
Alan A Musso	director	FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Susan L. Drexler	officer: See Remarks	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Muneer A Satter	10 percent owner	C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611
Reinhard J. Ambros	director	C/O AILERON THERAPEUTICS, INC., 281 ALBANY STREET, CAMBRIDGE MA 02139
Von Rickenbach Josef H	director	C/O PAREXEL INTERNATIONAL CORPORATION, WALTHAM MA 02451-1163
Jeffrey Allen Bailey	director	BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Vojo Vukovic	officer: SVP, Chief Medical Officer	C/O SYNTA PHARMACEUTICALS CORP., 45 HARTWELL AVENUE, LEXINGTON MA 02421
Kathryn Gregory	officer: SVP, Chief Business Officer	305 THAYER POND ROAD, WILTON CT 06897
William Mckee	director
Nolan Howard Sigal	director	941 BERRY AVENUE, LOS ALTOS CA 94024
Novartis Bioventures Ltd	10 percent owner	C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000
Rick Wanstall	officer: VP, Finance and Operations	C/O AILERON THERAPEUTICS, INC., 490 ARSENAL WAY, WATERTOWN MA 02472
Longenecker John P Phd	officer: President and CEO	10445 PACIFIC CENTER CT, SAN DIEGO CA 92121